Personalized chemotherapy for borderline pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a personalized approach to chemotherapy for people with borderline-resectable pancreatic cancer. It uses a lab test to find out if the cancer is likely to respond to a standard drug (gemcitabine), and if not, gives a different chemotherapy combination that might work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have borderline-resectable pancreatic ductal adenocarcinoma (a type of pancreatic cancer that is on the edge of being removable by surgery).
- Your cancer was confirmed by a biopsy (tissue sample).
- You are generally in good health (able to care for yourself and do daily activities).
- You have not had chemotherapy, radiation, or surgery for pancreatic cancer before (except one dose of a chemotherapy called mFOLFIRINOX while waiting for the test result).
- You are between 18 and 80 years old (if 75–80, a special health assessment is needed).
- You are enrolled in the PRODIGE 104 A NEOPREDICT study and your cancer tested negative for a gemcitabine sensitivity signature (a lab test showing the drug is less likely to work).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests giving chemotherapy before surgery for pancreatic cancer that is borderline removable. The chemo is chosen based on your tumor's genetic signature, which may make the treatment more effective and help shrink the tumor enough for successful surgery.
This trial studies whether giving chemotherapy before surgery, and possibly adding a focused high-dose radiation treatment, can improve outcomes for people with borderline resectable pancreatic cancer. It aims to shrink or control the cancer and help more patients get to surgery safely.
This trial compares two chemotherapy regimens — GnP (gemcitabine and nab-paclitaxel) and mFOLFIRINOX — given in alternating cycles for people with borderline resectable pancreatic cancer. The goal is to see if this alternating approach can shrink the tumor enough to allow surgery.
This trial tests giving chemotherapy before surgery for people with borderline resectable pancreatic cancer, to try to make surgery more successful. It also checks whether the study treatment is safe and helps tumors before the operation.
This trial is testing a new way to treat pancreatic cancer that has spread to nearby tissues but not to distant organs. It uses a tailored plan that may include chemotherapy and possibly surgery. The goal is to see if this personalized approach helps people live longer and better.
This trial tests a combination of two chemotherapy regimens (AG and FOLFIRINOX) with an immunotherapy drug (a PD-L1 antibody) before surgery for pancreatic cancer that is borderline resectable or locally advanced. The goal is to shrink the tumor enough to allow successful surgery.
Hear when a new Pancreas Adenocarcinoma (MSI-H) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.